Cantor Fitzgerald began coverage and issued rating, and Morgan Stanley upgraded price objective and rating for Silence Therapeutics.
4 reports, 3 independent
Updated Oct 22
Gone quiet
- Reports
- 4
- Developments
- 2
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Cantor Fitzgerald began coverage and issued rating, and Morgan Stanley upgraded price objective and rating for Silence Therapeutics.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Merck announced its acquisition of Silence Therapeutics amid analyst rating changes.1 source
Analyst coverage initiated by Cantor Fitzgerald and Morgan Stanley regarding Silence Therapeutics.1 source
Keep exploring
The entities involved
-
Silence Therapeutics
UK business
Nothing else this week.
-
Cantor Fitzgerald
American financial services company
-
Morgan Stanley
U.S. investment bank
Related events
- Cantor Fitzgerald, Citigroup, and MarketBeat issued rating updates and price targets for Rigel Pharmaceuticals, Inc.
- Cantor Fitzgerald reiterated an overweight rating for Sterling Infrastructure on November 1, 2026.
- Benzinga reported analyst research notes and Cantor Fitzgerald decreased its price objective for EMCOR Group, Inc.
- Cantor Fitzgerald restated an overweight rating for MoonLake Immunotherapeutics, which trades on Nasdaq, with data provided by MarketBeat.
- MarketBeat provided average ratings and price targets while Cantor Fitzgerald cut Ouster's rating to neutral.